Rabbit (polyclonal) Anti-p53 (pS^6) Phosphospecific Antibody, Unconjugated

PRODUCT ANALYSIS SHEET

Catalog Number:	44-641 (10 blot size)
Lot Number:	See product label
Quantity/Volume:	See product label
Form of Antibody:	Purified rabbit polyclonal immunoglobulin in phosphate buffered saline, pH 7.4.
Preservation:	0.02% sodium azide (Caution: sodium azide is a poisonous and hazardous substance. Handle with care and dispose of properly.)
Purification:	Purified from rabbit serum by epitope affinity chromatography.
Immunogen:	This antibody was produced against a chemically synthesized phosphopeptide derived from human p53, corresponding to the serine 6 phosphorylation site.
Specificity:	This antibody recognizes p53 when phosphorylated at serine 6. p53, a critically important mammalian cell-cycle checkpoint protein, arrests the cell cycle and in many instances induces apoptosis in response to DNA damage or other types of cell stress. Loss or mutation of the p53 gene occurs in many human cancers. Although rapidly degraded in undamaged normal cells, treatment with DNA damaging agents causes the transient accumulation and activation of p53 with increased phosphorylation. Specifically, exposure of cells to UV light or ionizing radiation results in increased phosphorylation at serine residues 6, 9, 15, 20, 33, and 37. This phosphorylation influences p53's DNA binding properties and its ability to bind to a variety of cellular and viral proteins. Phosphorylation of serine 6 and serine 15 occurs rapidly in response to DNA damaging agents.
Species Reactivity:	Human. Other species were not tested.
Applications:	This antibody is suitable for use in ELISA, Western blotting, and immunoprecipitation.
Suggested Working Dilutions:	The recommended concentration for use in immunoprecipitation is 3-5 µg/extract from 10^7 cells; for Western blotting, 0.5-2.0 µg/mL; and for ELISA, 0.1-1.0 µg/mL. The optimal concentration should be determined for each specific application.
Recommended Positive Control:	MCF-7 cells (breast adenocarcinoma cell line), treated with actinomycin D.
Storage:	Store at 2-8°C for up to one month. For long term storage, apportion into working aliquots and store at –20°C. Avoid repeated freeze-thaw cycles to prevent denaturing the antibody.
Expiration Date:	Expires one year from date of receipt when stored as instructed.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com
Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44641 (Rev 11/08) DCC-08-1089

References:

Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331 (Review).

Prives, C. and P.A. Hall (1999) The p53 pathway. J. Pathol. 187:112-126 (Review).

Brown, J.M. and B.G. Wouters **(**1999) Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1391-1399 (Review).

Albrechtsen, N., I. Dornreiter, F. Grosse, E. Kim, L. Wiesmuller, and W. Deppert (1999) Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18:7706-7717 (Review).

Wang, L., Q. Wu, P. Qiu, A. Mirza, M. McGuirk, P. Kirschmeier, J.R. Greene, Y. Wang, C.B. Pickett, and S. Liu (2001) Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J. Biol. Chem. 276:43604-43610.

Xirodimas, D., M.K. Saville, C. Edling, D.P. Lane, and S. Lain (2001) Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 20:4972-4983.

Backlund, M.G., S.L. Trasti, D.C. Backlund, V.L. Cressman, V. Godfrey, and B.H. Koller (2001) Impact of ionizing radiation and genetic background on mammary tumororigenesis in p53-deficient mice. Cancer Res. 61:6577-6782.

Sakaguchi, K., S. Saito, Y. Higashimoto, S. Roy, C.W. Anderson, and E. Appella (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275:9278-9283.

Higashimoto, Y., S. Saito, X.H. Tong, A. Hong, K. Sakaguchi, E. Appella, and C.W. Anderson (2000) Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents. J. Biol. Chem. 275:23199-23203.

Banin, S., L. Moyal, S. Shieh, Y. Taya, C.W. Anderson, L. Chessa, N.I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.

Canman, C.E., D.S. Lim, K.A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M.B. Kastan, and J.D. Siliciano (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679.

Burns, T.F. and W.S. El-Deiry (1999) The p53 pathway and apoptosis. J. Cell Physiol. 181:231-239 (Review).

Oren, M. (1999) Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274:36031-36034 (Review).

Lakin, N.D. and S.P. Jackson (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644-7655 (Review).

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44641 (Rev 11/08) DCC-08-1089